NCT04223024View on ClinicalTrials.gov

Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

August 31, 2024

Study Completion Date

December 31, 2026

Conditions
Nasopharyngeal Carcinoma
Interventions
DRUG

CCRT+Nimotuzumab

concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy) + Nimotuzumab (200mg, once a week during radiotherapy, a total of 7 weeks)

DRUG

CCRT alone

concurrent cisplatin (100mg/m2, every three weeks,D1,D22,D43 of intensity modulated radiotherapy )

Trial Locations (1)

510060

Sun Yat-sen Universitty Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER